Fierce is hiring! Senior editors and staff writers covering biotech, medtech and pharma. Look for job posts on Journalism Jobs and via our corporate job portal. careers-questex.icims.com/jobs/search?ss… #journojobs #journalismjobs Journos of Color Writers of Color

The White House has resumed the search for a permanent FDA commissioner in the face of opposition from D senators to Janet Woodcock. A final decision has not been made, but Woodcock's chances are slipping. Josh Sharfstein, is no longer being considered. biocentury.com/article/634529

Yikes! The number of clinical trials for #oncology #drugs dropped by 60% during #COVID19 pandemic period Medidata JAMA Network Open drugch.nl/3ud4hDE Fewer new therapies will be launched in coming years. That's the wrong way to curb drug spending.

Trending on Fierce Pharma (still)—$LLY and its #diabetes candidate posing a potential threat to Novo's star Ozempic fiercepharma.com/marketing/watc…

Scouting for smart journalists who'd like to make a difference covering the science and business of the pandemic. Medtech, biotech, pharma—we're an ambitious and growing team. #journojobs posts link below, or DM me: careers-questex.icims.com/jobs/search?ss…

Lots of Moderna news yesterday/today: booster shot study, new production targets, CMO exit and $18 billion in expected COVID vaccine sales this year. Up from about $11 billion they projected just last month. fiercepharma.com/pharma/moderna…

My 5 "perfect storm" worries for Texas: 1. "No vaccines" we still haven't picked up the pace post Ice Harvey, ranking near bottom for vaccinations. 2. No masks 3. Rising B..1.1.7 variant based on new Houston Health wastewater data. 4. Slight rise in positivity 5. Spring Break

New rule....investors start preferring public AdComs. No more cheering when a drug doesn't get one. It's the strongest part of the regulatory process that brings out truth. Keeps companies honest.

Dog lovers and word lovers -- you have to read this Fierce Medtech story. fiercebiotech.com/medtech/dogtor…

Update on the elephants: they are still on the outskirts of Kunming, and have the most adorable sleeping formation

$ABBV is down 10% after the FDA said makers of JAK inhibitors must add warnings of heart conditions, blood clots, cancer and death to their labels. This also impacts $PFE and $LLY. This doesn't pertain to drugs from $INCY and $BMY, however.

It’s deja vu all over again. These are the questions that the FDA Advisory Committee unanimously decided more than a year ago had not been answered for aducanumab. The FDA’s accelerated approval has been a pointless disaster for people with Alzheimer’s and our Field.

Fierce Biotech has been named as a finalist for 3 regional and 2 national Azbee Awards of Excellence! See our award-winning coverage below asbpe.org/news/2022/03/0…

Really proud of the biotech, healthcare and pharma editorial teams here at Fierce. We have a raft of finalist nods in the Neal awards, plus more in the Azbees. Check out both threads below for the stories and news coverage that rated.

Last day to vote in this round of FiercePharma's 2022 #FierceMadness drug name tournament! Check out the bracket below and then vote here: mollywalker8418.survey.fm/fiercemadness-…

Lots of incredible healthcare leaders on FierceHealthcare's Bracket. You can submit your #FierceMadness votes here. fiercehealthcare.com/special-report…

One of my favorite parts of FiercePharma's drug name Madness is the "sounds like" critiques from our readers. Airport wifi, fire-breathing dragon, Megan Thee Stallion duet partner ... and more.

Nice interview with FDA's Richard Pazdur from FierceBiotech and Angus Liu as we head into #AACR2022 this weekend.

BIO returns in-person with biotechs, Big Pharmas looking to make real life connections to survive bear market, Max Bayer reports from San Diego #BIO2022 fiercebiotech.com/deals/after-th…

Live from BIO 2022! Here's a short excerpt from Max Bayer's sit-down interview with Bayer | Pharmaceuticals president Sebastian Guth.